41
  • Anti-QSOX1 Antibody for Treating Cancer and Metastasis (No. T4-1642)

    Scientist: Deborah Fass

    A potential target for anticancer drug design.Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid tumors remain resistant to conve ... Read more
    5560
  • Antibodies Directed to ErbB Ligandsfor Treating Cancer (No. T4-1549)

    Scientist: Yosef Yarden

    A tailor-made strategy for cancer treatment. The ErbB family of tyrosine kinase receptors and their ligands play important roles in development and tissue remodeling throughout adulthood. ErbB proteins are involved in several types of human cancer. Clinical studies indicate that over-expression of one or more ErbB ligand ... Read more
    5509
  • Antibody Combinations in Treating Cancer (No. T4-1518)

    Scientist: Yosef Yarden

    Improved immunotherapy for breast cancer. Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness of therapeutic mAbs and the evolu ... Read more
    5497
  • Bioengineered Microorganisms that can "Eat" (Fix) CO2 (No. T4-1736)

    Scientist: Ron Milo

    Biomass production by plants and other photosynthetic organisms involves carbon fixation, the process of incorporating inorganic carbon dioxide into organic compounds. Currently carbon fixation by plants and other photosynthetic organisms is the limiting factor in biomass production. Improvement in the metabolic pathway ... Read more
    5608
  • Biological Treatment for Pancreatic Cancer (MMP7 mAb) (No. T4-1640)

    Scientist: Irit Sagi

    The innovative concept leading to this high selectivity is immunization with both a synthetic metal-protein mimicry molecule, previously developed by the present inventors, followed by the metalloenzyme itself (e.g. MMP-7). The resulting antibody exhibits exceptional degree of specificity towards MMP-7 over other MMPs.Th ... Read more
    5557
  • CD84 - a Novel Regulator of B-CLL Survival (No. T4-1441)

    Scientist: Idit Shachar

    Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of leukemia each year. Presently, there is no cure for CLL, and the overall ... Read more
    5470
  • Cholesterol Antibodies (No. T4-1267)

    Scientist: Lia Addadi

    Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes. Originally raised against an artificial monolayer of lipid mixtures in, and were shown to specifically label the above domains in different cell ... Read more
    5449
  • Disrupting or Preventing Formation of Biofilm by Enzyme Inhibitors (No. T4-1893)

    Scientist: Ilana Kolodkin-Gal

    Biofilm is a complex colony of bacteria, which are attached together by extracellular polymeric substance. This setting provides the bacteria protection against environmental factors, improves their surface attachment, and plays a major role in resistance to treatment. Therefore, biofilms are difficult to eradicate, much ... Read more
    5731
  • ERBB2 as a Novel Target to Treat Heart Failure by Inducing Cardiomyocyte Proliferation (No. T4-1752)

    Scientist: Eldad Tzahor

    Existing treatments fail to compensate the irreversible loss of functional cardiomyocytes (CM), thus presenting a major medical unmet need. Inducing native CM replacement is one approach being tested as regenerative treatment, with the advantage of a more straightforward methodology over cell transplantation approaches. ... Read more
    5623
  • Fully Naive Induced Human Pluripotent Stem Cells (iPSC) (No. T4-1671)

    Scientist: Jacob (Yaqub) Hanna

    A novel method to revert human iPSC to a fully naive state, retaining stable pluripotency. The feasibility for the existence of ground state naive pluripotency in human embryonic stem cells (hESC) has long been researched. This innovative technology supplies the composition of chemically defined conditions required for d ... Read more
    5578

Pages

Subscribe to Pharmaceuticals